Flamel notified of FDA to unapproved manufacturers of neostigmine methylsulfate Flamel Technologies has received communication from the FDA that all manufacturers of unapproved versions of neostigmine methylsulfate have been notified by the FDA to cease manufacturing of the unapproved product as of July 30. Current inventory in the channel of the unapproved product can continue to be sold. Flamel has not been provided with information on the inventory levels held by these manufacturers.
News For FLML From The Last 14 Days
Check below for free stories on FLML the last two weeks.